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Abstract
In human cancers, the methylation of long interspersed nuclear element -1 (LINE-1 or L1) retrotransposons is reduced. This
occurs within the context of genome wide hypomethylation, and although it is common, its role is poorly understood. L1s
are widely distributed both inside and outside of genes, intragenic and intergenic, respectively. Interestingly, the insertion
of active full-length L1 sequences into host gene introns disrupts gene expression. Here, we evaluated if intragenic L1
hypomethylation influences their host gene expression in cancer. First, we extracted data from L1base (http://l1base.
molgen.mpg.de), a database containing putatively active L1 insertions, and compared intragenic and intergenic L1
characters. We found that intragenic L1 sequences have been conserved across evolutionary time with respect to
transcriptional activity and CpG dinucleotide sites for mammalian DNA methylation. Then, we compared regulated mRNA
levels of cells from two different experiments available from Gene Expression Omnibus (GEO), a database repository of high
throughput gene expression data, (http://www.ncbi.nlm.nih.gov/geo) by chi-square. The odds ratio of down-regulated
genes between demethylated normal bronchial epithelium and lung cancer was high (p,1E
227; OR=3.14; 95% CI=2.54–
3.88), suggesting cancer genome wide hypomethylation down-regulating gene expression. Comprehensive analysis
between L1 locations and gene expression showed that expression of genes containing L1s had a significantly higher
likelihood to be repressed in cancer and hypomethylated normal cells. In contrast, many mRNAs derived from genes
containing L1s are elevated in Argonaute 2 (AGO2 or EIF2C2)-depleted cells. Hypomethylated L1s increase L1 mRNA levels.
Finally, we found that AGO2 targets intronic L1 pre-mRNA complexes and represses cancer genes. These findings represent
one of the mechanisms of cancer genome wide hypomethylation altering gene expression. Hypomethylated intragenic L1s
are a nuclear siRNA mediated cis-regulatory element that can repress genes. This epigenetic regulation of retrotransposons
likely influences many aspects of genomic biology.
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Introduction
In cancer, DNA methylation in the rest of the genome,
particularly at a long interspersed nuclear element-1 (LINE-1 or
L1) retrotransposon, is generally depleted and this event occurs
within the context of genome wide or global hypomethylation
[1,2,3]. Global hypomethylation may play several roles in
multistep carcinogenesis. Most commonly recognized effect is to
facilitate chromosomal instability [4], probably mediated by
hypomethylated genome associated replication independent
DNA double strand break error prone repair [5,6]. Recently,
there is a report that hypomethylation of a L1 activates alternate
promoter of MET oncogene [7]. However, the role of global L1
methylation, on genome wide gene expression, is less frequently
studied and thus not well-characterized.
DNA methylation is a fundamental molecular characteristic of
the human genome, and alteration of this epigenetic regulation is
associated with cancers [2]. The effects of promoter methylation
on chromatin configuration and gene transcription have been
well-documented [8]. In contrast, the mechanisms, how DNA
methylation within a gene (gene body methylation) controls gene
expression, are less known. Gene body methylation changes may
possess several consequences. Unique methylated sequences in
introns are frequently found in highly expressed genes [9]. In
contrast, the formation of heterochromatin by dense intragenic
DNA methylation limits the efficiency of RNA polymerase [10].
Nevertheless, these evidences implied that methylation of
intragenic repetitive sequences, including L1s, may also be
important for maintaining the normal function of linked genomic
loci.
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has several potential functional consequences [12]. It is notable
that L1s are not evenly distributed [11] and many are excluded
from genomic regions containing housekeeping genes [13]. A
genetically engineered in vitro study demonstrated that the
insertion of active L1 sequences into host gene introns disrupts
gene expression [14]. Throughout evolution, retrotransposition
events produced .500,000 copies of L1 in the human genome
[15]. However, not all L1s are full length and active; most are
truncated. There are 80–100 retrotransposition-competent L1s in
the human genome, but only six of these are thought to underlie
all historic retrotransposition events [16]. More than 10,000 L1s
are longer than 4.5 kb and contain a 59 UTR, two open reading
frames and a 39 UTR that features a polyadenylation signal [17].
More than 2,000 of these L1s are intragenic, and they reside
within more than 1,000 genes.
Recently, we evaluated the methylation patterns of the 59 UTRs
of L1 sequences [1,18] and found that methylation levels vary at
each locus and in different cell types in wild-type cells. In human
cancers, the methylation of L1 retrotransposons is reduced
variably [1,18,19]. The loss of genome wide L1 methylation in
cancerous cells occurs as a generalized process. However, L1
methylation is influenced by its location in the genome [18]. For
example, L1s in different introns of the same genes are generally
modified in a similar way [18]. L1 hypomethylation is correlated
with certain cellular phenotypes. In cancer, L1 hypomethylation is
directly associated with multistep carcinogenesis and aggressive
cancers with poor prognoses [1,20,21,22,23,24]. Moreover, in
normal cells methylation of L1 may be altered in association with
certain cellular phenotypes such as high cancer risk, tissue
differentiation and dietary [25,26,27,28,29,30,31,32,33]. Interest-
ingly, intersperse repetitive sequence (IRS) hypomethylation
patterns are different in cells with different phenotypes. For
example, Alu hypomethylation is commonly found in aging cells,
but L1 hypomethylation is not [34]. These lines of evidence lead
us to hypothesize that thousands of genes may be regulated by
intragenic L1 hypomethylation in cancerous cells.
Here, we extracted data from L1base (http://l1base.molgen.
mpg.de) [17], a database containing putatively active L1
insertions, to compare intragenic and intergenic L1 characters.
Then, we compared mRNA levels from hypomethylated normal
cells and cancer expression array libraries, available from Gene
Expression Omnibus (GEO), a database repository of high
throughput gene expression data, (http://www.ncbi.nlm.nih.
gov/geo) [35,36]. Finally, comprehensive analyses between L1
locations and genome wide gene expression were performed to
evaluate gene regulatory mechanisms of intragenic L1s in cancer.
Results
Intragenic and intergenic L1 sequences show distinct
structural features
Sequence variants of each long L1 are classified according to
evolutionary period and retrotransposition activity [17]. Here, we
analyzed if L1s are distinguishable depending on locations if the
sequences are within genes, intragenic, or in between genes,
intergenic (Fig. 1A). Various characteristics, described in L1base
[17] including chromosomal location, subfamily, sequence and
CpG islands, of 9,355 intergenic L1s and 2,546 intragenic L1s
found in 1,454 genes were evaluated by 218 chi-square tests and
18 t-tests (Supporting Table S1 and S2). Examples of a chi-square
test and a t-test were demonstrated (Fig. 1B and 1C). Statistical
analysis revealed that there are numerous structural characteristics
of intragenic L1s that are distinct from intergenic L1s (Fig. 1 and
Supporting Table S2). 100 chi-square tests analyzed variations of
the sequences that determine L1 transcriptional and retrotrans-
positional activity and the presence of CpG islands and 57 of the
tests were significantly different at p values ,0.001 (Fig. 1D and
Supporting Table S2). These tests showed the prevalence’s of
conserved sequences of intragenic L1s were always higher than
intergenic L1s whereas all mutated sequences were more common
in intergenic L1s (Fig. 1D and Supporting Table S2). In addition,
more frequent CpG islands were observed in intragenic L1s
(Fig. 1D and Supporting Table S2). This finding was supported by
comparing means of 18 features by t-test (Fig. 1C, 1E and
Supporting Table S2). Intergenic L1s contain more A and T
nucleotides, frameshifts, gaps and stop codons. In contrast,
intragenic L1s contain higher G-C contents and intactness score
(Fig. 1E and Supporting Table S2). In conclusion, intragenic L1
sequences have been conserved across evolutionary time with
respect to transcriptional activity and CpG dinucleotide sites for
mammalian DNA methylation. These findings implied physiolog-
ical functions of intragenic L1 methylation.
Intragenic L1s repress genes in cancer cells
L1s are hypomethylated in many cancers [1]. To investigate
whether intragenic L1s control host genes in L1 hypomethylated
cancer cells, we compared gene expression in cancer between
genes possessing intragenic L1s and the rest. Genes possessing L1s
were determined by L1base [17] and expression microarray data is
publicly available data from the GEO [35,36]. Each gene was
classified by 2 student t-tests, up- and down-regulations. If the
mean of cancer group was statistically higher or lower than normal
group, the gene was classified as up- or down-regulated,
respectively. If t-test was not statistically significant, the gene was
classified as not up- or not down-regulated, respectively. The
distribution of genes possessing L1s which showed the increased
expression in cancer was compared with the rest of gene set by chi-
square tests (Fig. 2A). The same analysis was performed for genes
with decreased expression in cancer (Fig. 2B). Figure 2A and 2B
demonstrated examples of chi-square tests of gene expression in
gastric cancer. Genes possessing intragenic L1s were found less
likely to be up-regulated (odds ratio (OR)=0.61, p=3.04E206)
(Fig. 2A). Moreover, expression of genes containing L1s were more
commonly decreased (OR=1.64, p=2.66E213) (Fig. 2B). Intra-
genic L1s may control hundreds of genes. Among 1,340 genes
containing L1s, 1,242 genes were not up-regulated and 304 genes
were down-regulated (Fig. 2A and 2B). Analysis of a number of
expression arrays showed similar results. We tested head and neck
squamous cell carcinoma, cervical cancer cells, lung adrenocarci-
noma cells, liver cancer, breast cancer cells, ductal and lobular
breast cancer, bladder carcinoma situ, microsatellite instable
gastric cancer, metastasis prostate cancer. We found that genes
down-regulated in cervical cancer cells, lung adrenocarcinoma
cells, breast cancer cells, ductal and lobular breast cancer, bladder
carcinoma situ, microsatellite instable gastric cancer are more
likely to contain L1s. Moreover, genes with higher expression
levels in head and neck squamous cell carcinoma, cervical cancer
cells, liver cancer, breast cancer cells, bladder carcinoma situ,
microsatellite instable gastric cancer, metastasis prostate cancer
are less likely to possess L1s (Supporting Table S3 and Fig. 2C).
Therefore, intragenic L1s may repress host genes in these cancers.
Although in vitro insertion of active L1 sequences into host gene
introns disrupted gene expression [14], most mRNA levels from
genes containing L1 were not absent (Supporting Fig. S1).
Moreover, a comparison of genes in cancer, as described in
supporting table S3.1–S3.9, showed that the probability of genes
containing L1 to be commonly down-regulated in independent
LINE-1 Represses Transcription in Cancer
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mean L1=1.6642, mean no L1=1.4861) (Supporting Fig. S2).
These analyses supported biological significance of intragenic L1s
in gene regulation in cancer.
To demonstrate the relation pattern between L1 methylation
levels and gene expression, we measured intragenic L1 methyla-
tion levels and host gene’s mRNA level. Previously, we evaluated
methylation levels of 17 intragenic L1 loci and found that the L1
methylation levels of L1-EPHA3-IVS5 and L1-EPHA3-IVS15 are
strongly correlated in cancer cells, suggesting locus specific
mechanism [18]. Measurement of intragenic L1-EPHA3 methyl-
ation and EPHA3 mRNA levels in head and neck squamous cell
cancer (HNSCC) cell lines (WSU-HNs) revealed that lower levels
of intragenic L1-EPHA3-IVS5 and L1-EPHA3-IVS15 methyla-
tion correlated with lower EPHA3 mRNA levels (Pearson
r=0.7961 and 0.7638, respectively; Fig. 2D). EPHA3 mRNA in
Figure 1. Intragenic L1s are conserved. A) L1s were divided into two classes, intragenic and intergenic L1s which are represented by blue and
red arrows, respectively. B) The differences in structural characteristics between L1 groups were analyzed using the chi-square test, for categorical
features and C) homoscedastic t-test for non-categorical features. D) 100 p-values of chi-square tests of three classes of L1 sequence characters, the
conserved sequences, the mutated sequences and the presence of CpG islands, that are found overrepresented or underrepresented in intragenic
L1s were displayed, intragenic L1s.intergenic L1s and intergenic L1s.intragenic L1s, respectively. E) 18 p-values of t-tests of L1 characters that are
overrepresented and underrepresented in intragenic L1s were shown in blue, intra.inter, and red color, inter.intra, respectively.
doi:10.1371/journal.pone.0017934.g001
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was hypomethylated (paired t-test; p,0.001; Fig. 2D). Therefore,
the level of mRNA can be directly correlated with intragenic L1
methylation.
Loss of methylation in normal cell represses genes that
harbor L1s
An analysis of gene expression in human bronchial epithelial
cells (hBECs) and human mesenchymal stem cells (hMSCs) after
genome wide demethylation by 5-aza-29-deoxycytidine (Aza-dC)
treatment demonstrated a greater prevalence of intragenic L1s in
down-regulated genes (OR=1.52, p=0.0017 and OR=1.62,
p=0.0069, respectively) (Fig. 2E, 2F and Supporting Table S3),
interestingly, a similar pattern as found in cancer (Fig. 2C). We
further explored if genome wide hypomethylation regulated genes
in cancer. We performed a chi-square test to determine the
significance of overlap between down-regulated genes in demeth-
ylated hBECs and in lung cancer. Genes which were down-
Figure 2. Intragenic L1s repress gene expression in cancer in the same pattern as demethylated normal cells. A) and B) are chi-square
262 tables, p values and odds ratios, comparing proportions of gastric cancer genes possessing L1s between up- (‘‘Up’’) or down- (‘‘Down’’) regulated
and not up- or not down-regulated groups, respectively. C) Percentages of L1-containing mRNAs that are up- or down-regulated in various cancer
types. D) EPHA3 mRNA and L1-EPHA3-IVS5 and IVS15 methylation levels in WSU-HN cells and Aza-dC-treated WSU-HN17s. E) Two chi-square 262
tables, p values and odds ratios, comparing proportions of Aza-dC-treated hBECs or hMSCs genes possessing L1s between down-regulated (‘‘Down’’)
and not down-regulated groups, respectively. F) % of mRNAs from genes containing L1s in Aza-dC-treated hBECs and hMSCs. ‘‘Up’’ and ‘‘Down’’
indicate increased and decreased expression, respectively. GSE records, GSM samples and type of t-test and 262 tables of chi-square tests are
provided in Supporting Table S3.
doi:10.1371/journal.pone.0017934.g002
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preferentially have lower mRNA levels in the cancerous cells of
the lung (p=2.67E228; OR=3.14; 95% CI=2.5423.88;
Figure 3A and 3B and Supporting Table S4). This supports the
hypothesis that hypomethylation down regulates genes in cancer.
Interestingly, hypomethylation down regulates both groups of
genes, with L1 (p,2.59E204; OR=3.24; 95% CI=1.7326.05;
Supporting Table S4) and without L1 (p,2.34E224; OR=3.09;
95% CI=2.4623.87; Supporting Table S4). Therefore, it is
possible that in addition to L1 there are other DNA methylated
gene body elements that regulated gene expression. This
hypothesis is supported by a recent report that, in gene body,
unique methylated sequences are more prevalence in highly
expressed genes [9]. To further differentiate the role of L1s, we
compared between genes with and without L1s. We found that the
event of down-regulation of genes in both Aza-dC treated hBECs
and lung cancer is more prevalent in genes containing L1s than in
genes without L1. (OR=2.08, p=0.009; Fig. 3C and 3D and
Supporting Table S5). Therefore, hypomethylation decreases the
expression of many genes in cancer, and intragenic L1s act as a
methylation-mediated cis-regulatory element.
Many genes frequently downregulated in cancer display
hypermethylated promoters [8]. However, we found no connection
between promoter hypermethylation in cancer and the presence of
intragenic L1s. Genes with hypermethylated promoter have been
shown to be up-regulated when cells were demethylated. The
expression of genes with L1 was not frequently increased when
cancer cells were demethylated (Supporting Table S6.1 and S6.2).
L1 hypomethylation increases L1 RNA levels
Measurement of methylation and RNA levels showed an inverse
correlation between genome wide L1 methylation and L1 RNA
(Pearson r=20.6955; Fig. 4A). This finding supports the
hypothesis that L1 hypomethylation increases L1 RNA transcrip-
tion [37]. Intronic genes have been proposed to form aberrant
RNA complexes with host genes and consequently inactivate host
gene transcription [38]. L1s are retrotransposable elements that
may still possess transcriptional activity at a significant number of
loci [29]. Moreover, some L1s are transcribed beyond their polyA
addition sites and consequently produce chimeric RNAs that
include both L1 and unique intronic sequences [39]. We screened
for and found L1-EPHA3 RNA from intron 15 of the EPHA3
gene and observed a significant inverse association between L1-
EPHA3 RNA and L1-EPHA3 methylation (Pearson r=20.8686;
Fig. 4B). Therefore, L1 hypomethylation leads to increased L1
transcription and consequently produces more intronic L1 RNA.
Intragenic LINE-1 elements repress transcription in
cancer cells through AGO2
Retrotransposon RNAs or transcripts forming dsRNA structures
trigger RISC assembly [40]. After binding small interfering RNAs
(siRNA), RISC recognizes and degrades complementary RNA
molecules [41]. L1s possess up to three internal promoters, at the 59
and 39 ends and in the 59 antisense direction [42,43,44]. The sense
and antisense promoters in the 59 UTR produce bidirectional
transcripts that are subsequently processed into siRNAs to prevent
Figure 3. Demethylated genome and hypomethylated intragenic L1s repress gene expression in cancer. A) 262 tables, p values and
odds ratios and B) odds ratio for mRNAs that are under-expressed (‘‘Down’’) in lung cancer and Aza-dC-treated hBEC cells compared to non-Aza-dC-
treated hBEC cells for (A and B) all genes, (B) genes with L1s (L1) and genes without L1s (No L1). B) The middle, top and bottom lines of each two-
color box are the odds ratio and upper and lower 95% confidence interval (CI), respectively. C) 262 tables, p values and odds ratios and D)
percentages of mRNAs that are under-expressed (‘‘Down’’) in both Aza-dC-treated cells and cancer cells compared with genes that are not
downregulated in Aza-dC-treated cells or cancer, for genes with and without L1s (L1 and No L1). The corresponding 262 contingency tables for A)
and B), and C) and D) are provided in Supporting Tables S4, and S5, respectively.
doi:10.1371/journal.pone.0017934.g003
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and intronic pre-mRNA of genes containing L1s, because of
complementarity of both sequences, form dsRNA which may be
targeted by RISC, consequently depleting the amount of mRNA
derived fromgenescontainingL1s.TheRISCcomplexiscomposed
ofDicer,ArgonauteandsiRNA.A similarcomplex with AGO2 acts
to silence gene transcription in the nucleus [45,46].
If intragenic L1 RNA reduces host gene mRNA via AGO2,
AGO2 protein deprivation will result to increase mRNA levels of
genes hosting L1s. Analysis of mRNA microarray of AGO2 down-
regulated cells, AGO2sh [47], demonstrated that the limited
expression of AGO2 in a human embryonic kidney cell line
(HEK293T) resulted in an expression pattern of gene containing
L1s that was opposite from that observed during L1 hypomethyla-
tion; namely, they were more likely to be up-regulated (OR=1.44,
p=0.0004; Fig. 5A and 5B and Supporting Table S3). The
shRNAs of DICER1, AGO1, AGO3 and AGO4 did not
upregulate genes with L1 (Supporting Table S6.32S6.7). This
suggested that AGO2 preferentially limits the concentration of
mRNAs derived from genes containing L1s. We further evaluated
an mRNA microarray experiment hybridized by AGO2 precip-
itated RNA [48] and found that AGO2 may not directly degrade
mRNAs that are derived from genes containing L1s. Although
RISC binds and degrades mRNA, mRNAs derived from genes
containing L1s were less likely to be bound by AGO2 (OR=0.64,
p=0.009; Fig. 5A and 5B and Supporting Table S3), which was
initially surprising given the results of the AGO2sh experiments
(Fig. 5A and 5B and Supporting Table S3).
When comparing AGO2-bound mRNAs to AGO2sh-upregu-
lated genes, we found that for mRNAs derived from genes without
L1, AGO2 significantly bound to mRNAs that were enriched when
cells were treated with AGO2sh (OR=1.43, p=0.001; Fig. 5C and
5D and Supporting Table S4). This confirmed that AGO2 targets
and degrades these mRNAs. In contrast, the mRNAs of genes
containing L1s do not bind significantly to AGO2 even if they are
up-regulatedbyAGO2sh(OR=1.05,p=0.90;Fig.5Cand5Dand
Supporting Table S4). The down-regulation of AGO2 also
increased EPHA3 mRNA and L1RNA levels in WSU-HN17 cells
(p,0.01; Fig. 5E). Significant alteration of L1 methylation was not
observed by AGO2sh (p=0.942). Therefore, even though AGO2
preferentially down-regulates genes containing L1s, itdoes not do so
by binding to their mRNAs. Because most intragenic L1s are
located in introns, pre-mRNAs, particularly intronic sequences, are
the preferable AGO2 targets (Fig. 5F).
Here we provided an example of AGO2 binding with L1-
associated pre-mRNA. RNA immunoprecipitation and RT-PCR
confirmed that AGO2 binds to L1-EPHA3 RNA (Fig. 6A). We
used the information of genes containing L1 from L1base to
identify the up-regulated genes in AGO2 depleted HEK293T cell
lines, which have L1 in the gene body. Using this set of up-
regulated genes, Figure 6B shows the 2x2 contingency table
displaying a chi-square test of association between the presence of
L1 and AGO2 binding sites. AGO2 binding sites were found in all
L1-containing genes that were up-regulated in AGO2sh cells (124
out of 126 genes, OR=17.91, p=3.52E208). Focusing on the up-
regulated genes, we also observed the distribution of AGO2
binding sites on these genes in which L1 can be found in their
intronic regions. Numbers of AGO2 binding sites were counted if
they are found in the vicinity of L1 assuming that L1 is located
between any exons. Particularly, we created a histogram by
counting the number of AGO2 binding sites located within 600 kb
upstream and downstream of L1 using the 25-kb interval size
(Fig. 6C and 6D). Figure 6C and Figure 6D demonstrate the
frequency distribution of AGO2 binding sites with respect to
antisense L1 and sense L1, respectively. Interestingly, hundreds of
AGO2 binding sites were found at hypothetical locations
presenting double strand RNA between pre-mRNA and 59 or 39
L1 transduction sequence (Fig. 6C and 6D). These were sequences
nearby L1 at 59 direction from L1 toward gene transcriptional
start sites. Therefore, AGO2 preferentially regulates genes
containing L1s by targeting intragenic L1 RNAs with sequence
complementary to pre-mRNAs. Finally, the event of up-regulation
of genes in AGO2 depleted cells and down- or not up-regulated in
cancer was found more prevalent in genes containing L1s than in
genes without L1 (Fig. 7A–7E). Therefore, intragenic L1s act as a
AGO2-mediated cis-regulatory element in cancer.
Finally, we evaluated the correlation between expression
changes and the presence of intergenic L1s. We compared genes
with sense and antisense intergenic L1 within 1 or 2 kb from 59
and 39 of the genes (Supporting Table S7). Unlike genes
containing L1s, there are a limited number of genes with nearby
intergenic L1s. Interestingly, L1 within 1 kb from the end of the
genes prevented genes from up regulation (OR=0.23, p=0.03;
Supporting Table S7). In contrast, there was no regulatory
Figure 4. L1 hypomethylation increases L1 RNA. A) Genome wide L1 methylation and L1 RNA levels in WSU-HN cells. B) L1-EPHA3 methylation
and L1-EPHA3 RNA levels.
doi:10.1371/journal.pone.0017934.g004
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supported a possibility that L1 transcript in opposite direction can
repress the nearby genes.
Discussion
Our comprehensive analysis of genome and expression array
databases is a simple and useful approach to explore disease- or
biological process-related mechanisms that alter genome wide
gene expression patterns. Here, we showed that genes hosting
intragenic L1s are more likely to be repressed in cancer and that
the level of repression depends on the degree of L1 hypomethy-
lation. The degree of L1 hypomethylation varies at each locus
of each tumor and may change throughout the multistage
carcinogenesis process. In general, more advanced stages of
cancer are associated with a greater degree of hypomethylation
Figure 5. AGO2 and L1 RNA mediate intragenic L1 down-regulated gene expression in gene containing L1s. A) 262 tables, p values
and odds ratios and B) percentages of L1 containing-genes that exhibit increased mRNA levels in AGO2sh-treated cells (‘‘Up’’) or are bound by AGO2
in AGO2IP (‘‘Bound’’), respectively. C) 262 tables, p values and odds ratios and D) odds ratios (95% CI) comparing HEK293T mRNA between up-
regulated genes and not up-regulated genes upon AGO2sh and bound by AGO2 proteins for all genes (D), genes with L1s (L1) and genes without L1s
(No L1), (C and D). D) The middle, top and bottom lines of each two-color box are the odds ratios and upper and lower 95% CIs, respectively. E) Levels
of AGO2, EPHA3 mRNA and L1RNA in WSU-HN17 AGO2si cells. Data represent means 6 SEM. GSE records, GSM samples, type of t-test for A) and B)
are given in Supporting Table S3. 262 contingency tables for C) and D) are given in Supporting Table S4. F) Two scenarios of AGO2-target binding
reflecting in different mRNA array results when using AGO2-IP and AGO2sh as probes. Negative result was expected from mRNA expression
microarray using AGO2-IP RNA as probes, (‘‘AGO2-IP + mRNA array’’), when introns of pre-mRNA were targeted. However, positive result was
expected from mRNA expression microarray using mRNA from AGO2sh as probes, (‘‘AGO2sh + mRNA array’’), regardless AGO2 targets pre-mRNA or
mRNA.
doi:10.1371/journal.pone.0017934.g005
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sion in part due to increasing degrees of gene repression and
numbers of repressed genes.
It is important to note that the conclusion of our comprehensive
analysis between L1 locations and gene expression should not be
altered by L1 insertion dimorphisms (LIDs) of analyzed samples.
Figure 6. AGO2 binds intragenic L1 RNA and targets AGO2 regulated genes. A) RNA immunoprecipitation/RT-PCR. TRIM38 is a miRNA
binding site in intron of TRIM38. BCKDK and PSENEN are introns of the genes, lacking of miRNA binding site. RT- and RT+ are samples without and
with reverse transcriptase treatment, respectively. B) 262 contingency table, p-values and odds ratios of chi-square test and C) grouped frequency
distribution (histogram) of AGO2 binding sites corresponding with the location of antisense L1 with a 25-kb interval. and D) histogram of AGO2
binding sites corresponding with the location of sense L1 with a 25-kb interval.
doi:10.1371/journal.pone.0017934.g006
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identified as LIDs [50,51,52]. Nevertheless, majority if LIDs are
truncated and localized intergenics [50,51,52]. Therefore, the
number of intragenic long LINE-1 dimorphisms are low.
Moreover, L1Base reported L1 locations based on Homo sapiens
Genome: Statistics — Build 36 version 1. This suggests that most
L1s in L1Base are not newly inserted L1s and very few may
represent common LIDs. Consequently, the degree that LIDs
influence the complementary analysis was very low.
Many studies have reported the methylation of tumor
suppressor gene promoters in cancer cells; this epigenetic
regulation has become a potential candidate for biomarker and
therapeutic target development. To our knowledge, this is the first
study to demonstrate that global hypomethylation down-regulates
genes in cancer. Moreover, there may be several hypomethylation-
mediated cis-suppressor elements, including intragenic L1s.
Genome wide hypomethylation is common to many cancer types
[1]. Therefore, the hypomethylation sites and repressed genes
described here represent a vast number of molecular targets and
diagnostic markers.
Nevertheless, not all intragenic L1s can repress gene expression
in cancer, and L1s may regulate genes through several distinct
mechanisms. Even though L1 sequence analysis showed that
intragenic L1s have been conserved throughout human evolution,
their sequences and distributions do vary considerably. Moreover,
the methylation levels of some L1 loci are independent of genome
wide L1 hypomethylation in cancer [18]. Notably, Rangnawa and
colleagues [39] reported varying L1 RNA levels in normal cells
that generally feature a limited range of intronic L1 methylation
[18], suggesting that other factors also influence L1 expression.
Therefore, it is complicated but important to further explore L1
and genome characteristics that may determine their repression
properties in cancer cells.
Here, we identified one mechanism by which L1s can repress
genes in cancer. First, L1 hypomethylation increases L1 RNA
levels. Then, the AGO2 protein regulates genes possessing L1.
Finally, mRNA processing of genes harboring hypomethylated L1s
is disrupted. AGO2 was reported to commonly target L1 RNA
[40] and was proposed to prevent retrotransposition events [53].
However, the role of the L1-RNA-AGO2 complexes derived from
the majority of retrotranspositionally incompetent elements was
unknown. Moreover, there are several mechanisms by which
RISC can regulate gene expression [54]. This study also proposed
a new role for nuclear RISC complexes.
This study proved that intragenic L1 hypomethylation represses
genes via a post-transcriptionally mechanism, based on siRNA and
AGO2. However, it is possible that there are other mechanisms
that should be further explored such as the intereference with the
elongating RNA Pol2 transcribing their host genes or formation of
chromatin complex in relation with L1 methylation level.
In conclusion, intragenic L1 produces L1 RNA upon hypo-
methylation in cancer tissues, and the host gene is consequently
down-regulated when AGO2 is present. Further studies should
reveal additional factors that influence this process both in cis and
in trans, such as L1 sequence variations, boundary sequences,
methylation, chromatin configuration, location, transcription
factors that are correlated with the degree of L1 methylation,
molecules involved in the AGO2-intronic L1 RNA processing
mechanism and factors that guide or prevent AGO2 recognition.
In addition to their modifications in cancer, L1 and other IRS
methylation are altered by many biological processes including the
disease-related ones [1,18,25,26,29,30,34,55]. Therefore, it will be
interesting to explore whether changes in L1 and other IRS
methylation also regulate genes under these conditions.
Materials and Methods
Statistical analysis of L1 characters
L1s reported in L1base [17] were categorized according to their
genomic locations as ‘‘intragenic’’ or ‘‘intergenic’’ based on NCBI
Reference Sequence (RefSeq) annotation. The differences in
structural characteristics between L1 groups were analyzed using
the chi-square test and homoscedastic t-test for categorical and
non-categorical functionally important features, respectively. For
categorical features, the frequency of intragenic L1 features was
counted both according to the number of genes and the number of
L1 sequences that contained the tested features.
Classification of mRNA
mRNAs from GEO [35,36] were classified as up- or down-
regulated and not up- or not down-regulated depending on the
statistical significance determined by student’s t-test. The libraries
were GSE6631[56], GSE9750[57], GSE5816[58], GSE14811[59],
GSE1299[60], GSE5764[61], GSE3167[62], GSE13911[63],
Figure 7. AGO2 repress expression of gene containing L1 in cancer. The Chi-square test shows that the up-regulated genes in AGO2si and
the down-regulated (or not up) genes in A and B) bladder carcinoma and C and D) gastric carcinoma are associated with L1. The test and control are
of the same as in the Supporting Table S3.12, S3.7 and S3.8. AGO2 represses expression of gene containing L1 in cancer. The chi-square test shows
that the up-regulated genes in AGO2si and the down-regulated (or not up) genes in A) and B) bladder carcinoma and C) and D) gastric carcinoma are
associated with L1. The test and control datasets are the same as present in the Supporting Table S3.12, S3.7 and S3.8. E) The percentage of genes
that was both up-regulated by AGO2sh and repressed in cancer cells.
doi:10.1371/journal.pone.0017934.g007
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GSE14054[49]. A Student’s t-test was performed on all probes.
Someprobes represented more than one gene (homologous probes).
A gene was counted as differentially expressed (up- or down-
regulated) by expression level of at least one unique probe. If a gene
contained only homologous probes, there must be at least two
homologous probes representing the same gene. Up- or down-
regulated genes were counted when representing probes were
significantly different between test and control groups at p,0.01.
P,0.05 was used when the number of tests or controls was two or
mRNA was prepared by immunoprecipitation.
Expression of genes possessing internal L1s
To evaluate if intragenic L1s can influence host gene expression,
up- or down-regulated genes and genes without significantly
increased- or decreased- expression were divided into two
categories whether containing intragenic L1s or not. Genes
hosting L1s were listed in Supporting Table S1. The numbers of
genes in each subset were compared using a chi-square test
(Table 1).
Connection Up- or Down- Regulation Expression Analysis
of Microarrays (CU-DREAM)
CU-DREAM is a method for analyzing databases of two
expression arrays with different conditions to determine if the two
conditions share genome wide gene regulation pathway. First,
mRNAs from two different expression microarrays were classified
as up- or down-regulated and not up- or not down-regulated
depending on the statistical significance determined by student’s t-
test. From data of two arrays, each mRNA presented in both
experiments were classified into 4 groups: 1) regulated in both
array experiments, 2) not regulated only in the first experiment, 3)
not regulated only in the second experiment, and 4) not regulated
in both array experiments. The numbers of genes in each subset
were compared using a chi-square test (Table 2). Non random
distribution of these four groups indicated the connection of the
two variables if the two experiments promoted or inhibited the
same mechanism(s) that altered genome wide gene expression.
Cell preparation
Eleven HNSCC cell lines (WSU-HNs), including WSU-HN 4, 6,
8, 12, 13, 17, 19, 22, 26, 30 and 31, were provided by Dr. Silvio
Gutkind (NIH, USA). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco BRL, Life Technologies, Pairly,
UK) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Sigma, St. Louis, MO, USA). Cells were incubated at 37uCi n
5% CO2. To inhibit DNA methyltransferase (DNMT) activity,
WSU-HN cellswere supplemented with 4 mM 5-aza-2-deoxycytidine
(Cat.No. A3656 Sigma-Aldrich) every 24 hours for up to 16 days for
genomic demethylation. WSU-HN17 cells were transiently trans-
fected with siRNA against eIF2C2 mRNA (AGO2 siRNA), which
was designed by and purchased from Santa Cruz Biotechnology, Inc.
(eIF2C2 siRNA (h): sc-44409). A non-silencing siRNA with no
homology to any known mammalian genes (AllStars negative control
siRNA, QIAGEN, Basel, Switzerland) wastransiently transfected as a
negative control siRNA for each experiment.
L1 methylation analysis
The methods of genome wide L1 and specific loci L1
methylation measurements were extensively validated [1,18,34].
Briefly, genomic DNA was denatured in 0.22 M NaOH at 37uC
for 10 min. A 30 ml aliquot of 10 mM hydroquinone and 520 ml
3M sodium bisulfite were added and the DNA was further
incubated for 16–20 hrs at 50uC. The DNA was purified and
incubated in 0.33 M NaOH at 25uC for 5 min, ethanol-
precipitated, then washed with 70% ethanol and re-suspended in
20 ml TE buffer. A 2 ml sample of bisulfited DNA was subjected to
35 cycles of PCR with two primers as reported [1,18] at an
annealing temperature of 53uC. The amplicons were digested in
30 ml reaction volumes with 2U of TaqI or 8U of TasI in 1xTaqI
buffer (MBI Fermentas) at 65uC overnight and then electropho-
resed in 8% non-denaturing polyacrylamide gels. The intensities of
DNA fragments were measured with a PhosphorImager and
analyzed using ImageQuant software (Molecular Dynamics). The
methylated amplicons (TaqI positive) yielded 80 bp DNA
fragments while unmethylated amplicons (TasI positive) yielded
97 bp fragments. The L1 methylation level was calculated as a
percentage (the intensity of methylated L1 digested by TaqI
divided by the sum of the unmethylated L1 digested by TasI-and
the TaqI-positive amplicons). The same set of DNAs was applied as
a positive control in each set of COBRA experiments.
Reverse transcription (RT) PCR
Total RNA was extracted from cell lines using the Trizol
reagent (Life Technologies, Inc.) according to the manufacturer’s
instructions. The RNA was treated with RNase-free DNaseI(Fer-
mentas) to remove contaminating genomic DNA and with
RiboLock
TM Ribonuclease Inhibitor (Fermentas) to prevent
degradation. To synthesize cDNA, 5 mg DNA-free RNA was
dissolved in 12 ml of DEPC-treated water containing 0.5 mg
oligo(dT)18 primer (Fermentas). The RNA was incubated for
5 min at 70uC and chilled on ice for 5 min. Each sample was then
incubated with 200U RevertAid
TM M-MuLV Reverse Transcrip-
tase (Fermentas), 20 U Ribolock
TM Ribonuclease inhibitor
(Fermentas) and 20 mM dNTPs for 1 hr at 42uC, followed by
10 min at 70uC and subsequent chilling on ice. cDNA was
amplified using the exon primers listed in the Appendix. RNA that
had not been reverse transcribed was included as negative control
Table 1. 262 table of chi-square test to evaluate if intragenic
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Oligo(dT)18, random Hexamer and L1-EPHA3-IVS15-P1,
ACAAATACCATATCCTTCAAGACAAATCG, were used for
the RT step. The PCR oligonucleotides used were: L1-RNA,
CAGGAAGGGGAATATCACACTC and TGCGCTGCACC-
CACTAACTC; and 59L1-RNA, GGCCAGTGTGTGTGCG-
CACCG and CCAGGTGTGGGATATAGTCTCGTGG;
AGO2, CACAAGTTGGTTCTGCGCTA and TGAAACTTG-
CACTTCGCATC; GAPDH, TTCGCTCTCTGCTCCTCCT-
GTTC and CTGGTGACCAGGCGCCCAA; L1-EPHA3 RNA,
CTAACCTGCACAATGTGCACATGTACCC and L1-EPHA
3-IVS15F. For RNA immunoprecipitation experiment control
primers were, TRIM38, GCAAAAACCACAATTACTTTTG-
CAC and AAGAGAGAAAATTGGTAATCAGCTTG; negative
control, PSENEN, GGCACCCCAGCCGGAGGA and CGGGT-
CGTCCCAAGGGTCTG; and BCKDK, CCCACCATGATGC-
TCTACGCTGG and CCTTGATGCGGTGAGCAATCCTC.
Real-time RT-PCR was performed for 40 cycles with an annealing
temperature of 60uC. Real-time RT-PCR was performed in a Light
Cycler machine (Roche Molecular Biochemicals, Indianapolis, IN,
USA) using QuantiTect SYBR Green I (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. To quantitate gene
expression, each PCR product was cloned into the pGEM-T easy
vector (Promega, Santhan, UK) and used as controls. All mRNA,
L1 RNA and L1-EPHA3 RNA levels were normalized with
GAPDH, total RNA and band intensity, respectively. The highest
RT-PCR levels observed in each experiment were adjusted to 1.
RNA immunoprecipitation
AGO2 antibody (sc-32659) and goat IgG (sc-2028) (Santa Cruz)
were used to immunoprecipitate RNA as described (http://www.
epigenome-noe.net/researchtools/protocol.php?protid=28) [66].
Cells were grown in a 75 cm
2 flask at 80% confluence, washed
with PBS and trypsinized. Approximately, 1610
8 cells were added
to a 15 ml conical tube, pelleted, and resuspended in 10 ml 1%
formaldehyde in PBS. This crosslinking reaction was performed
for 30 minutes at room temperature and stopped by the addition
of glycine at a final concentration of 125 mM. The pellet was
washed twice with ice-cold PBS containing 16protease inhibitor
cocktail. The cell pellet was resuspended in 200 ml Buffer A (5 mM
PIPES (pH 8.0), 85 mM KCl, 0.5% NP40, 16 Roche protease
inhibitors cocktail, SUPERaseNin (50 U/ml)) and placed on ice for
10 minutes. The crude nuclei fraction was pelleted by micro-
centrifugation at 5000 rpm for 5 minutes at 4uC. The pellet was
washed once in Buffer A without NP-40, then resuspended in
500 ml Buffer B (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH
(8.1), 16Roche protease inhibitors cocktail, SUPERase in (50 U/
ml)) and incubated on ice for 10 minutes. Lysates were sonicated
three times at 4uC using a Branson Sonifier at constant power,
output=70%, and continuous sonication for 20 seconds. After
sonication, insoluble elements were cleared by microcentrifugation
at 14,000 rpm for 10 minutes at 4uC. The sonicate was diluted 10-
fold with IP Buffer to a final volume of 1 ml per immunoprecip-
itation reaction. A 1% aliquot was preserved as an input sample
and frozen at 280uC until the reverse crosslinking step. For the
precipitation step, 5 mg of primary antibody or a normal IgG
control was added to each tube. Immune complexes were allowed
to form by slow mixing on a rotating platform at 4uC overnight.
To collect immune complexes, 50 ml Protein A/G Agarose-PLUS
(Santa Cruz) was added to each tube and slow mixing rotation was
continued for 2 hours. Immune complexes were pulled down by
gentle centrifugation at 1000 rpm for 2 minutes at 4uC. Each
immune complex was washed five times (1 ml wash, 5 minutes
each). After each wash (low salt wash, high salt wash, LiCl wash
and 2 washes with TE pH 8.0), complexes were pelleted by gentle
centrifugation (1000 rpm, 1 minute) and the wash buffer was
aspirated using a clean pipette tip. Immune complexes were
eluted by the addition of 250 ml Elution Buffer and collected by
centrifugation (8000 rpm, 2 minutes). NaCl was added to a final
concentration of 200 mM (including the input samples) and
placed at 65uC for at least 2 hours to reverse crosslinking.
Samples were subjected to Trizol LS reagent extraction and
resuspended in 20 ml DEPC-treated water. DNA was removed
from the samples by treatment with RNase-free DNaseI
(Fermentas Inc.). TRIM38 was predicted to be positive. BCKDK
and PSENEN were predicted as negative controls. TRIM38 was
up-regulated in AGO2si experiment and possess a intronic
miRNA binding site [67]. BCKDK and PSENEN do not contain
miRNA binding site [67].
Localization of AGO2 target pre mRNA
The chromosomal locations of AGO2 binding sites were
retrieved from the CLIPZ database [68], which releases RNA-
binding protein (RBP) binding site data generated by cross-
linking and immunoprecipitation (CLIP) mapping technique.
Only AGO2 binding sites longer than 18 base pairs were
included in our study. We mapped the locations of AGO2
binding sites to human genome reference sequence hg18 (build
36.3) and then identified NCBI RefSeq target genes of AGO2.
The list of genes that contain AGO2 binding sites and also
contain L1 were obtained from intersecting the set of genes that
has at least one AGO2 target site with the set of L1-associated
genes inferred from L1base. The positions of AGO2 binding sites
in relative to L1 sequences were also calculated. To determine if
AGO2 works in concert with L1 in the regulation of gene
expression, the microarray data of AGO2 knock down
HEK293T-derived cell lines and control group [47] were used
for the analysis. These expression data were obtained from the
experiment GSE4246 deposited in the Gene Expression Omni-
bus (GEO) database [35,36]. Paired t-test with the p-value 0.05
cutoff was used to differentiate the up-regulated genes from
unchanged as well as down-regulated genes. The association
between the presence of L1 and AGO2 binding site was analyzed
using chi-square test.
Supporting Information
Figure S1 S1.1 shows the log-scale expression level of experi-
ment GSE3167 bladder carcinoma situ vs normal bladder
epithelium. The test and control are the same as shown in the
supporting table S3.7. S1.2 shows the log-scale expression level of
experiment GSE13911 microsatellite instable gastric cancer vs
normal stomach epithelium. The test and control are the same as
shown in the supporting table S3.8.
(PDF)
Figure S2 the distributions of genes commonly down-regulated
in the independent experiments compared between genes
containing L1 and genes without L1 including the list of L1-
containing genesfound to be down-regulated in at least one
experiment.
(PDF)
Table S1 Genes containing L1 sequences.
(PDF)
Table S2 Analysis of L1 characteristics.
(PDF)
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contingency tables of chi-square tests corresponding to the
expression analysis of genes possessing internal L1s.
(PDF)
Table S4 The 262 contingency tables corresponding to CU-
DREAM chi-square tests.
(PDF)
Table S5 The 262 contingency tables corresponding to genes
possessing internal L1s which were down-regulated in both cancer
and demethylated normal cells.
(PDF)
Table S6 List of GSE records and GSM samples, type of t-test,
and 262 contingency tables of chi-square tests for the analysis of
up-regulation in genes possessing internal L1s. The data were
displayed for expression in demethylated lung cancer cells (Table
S6.1 and S6.2), DICER1sh (Table S6.3 and S6.4), AGO1sh
(Table S6.5), AGO3sh (Table S6.6), and AGO4sh (Table S6.7).
(PDF)
Table S7 Odds ratios, p values and 262 contingency tables of
chi-square tests comparing between expression of genes possessing
nearby intergenic L1s and the rest of genes in bladder carcinoma
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